What you need to know about NASH
NASH, or non-alcoholic steatohepatitis, has been a hot space for pharma over the last few years, prompting major players to pour big bucks into dealmaking. Yet, as the first drugs reach late stages and near approval, companies are taking a step back to see how the data read out.
At the same time, preclinical and early-stage NASH assets are beginning to mature and bring with them the promise of a new wave of NASH drugs and more M&A activity.
BioPharma Dive is taking a deeper look at how this market is changing, the challenges drugmakers will face if they reach commercialization and the shifting market sentiment, including a conversation with a biotech exploring the genetics of the disease.
With the first NASH drugs expected to win approval over the next two to three years, drugmakers will face several major barriers to market entry. Read More »
Researchers at Regeneron found a genetic variant associated with lower risk of chronic liver disease. Lacking the tools to turn the discovery into a drug, the biotech partnered with Alnylam. Read More »
The fatty liver disease has dozens of treatments in the global pipeline. But investors are treading lightly, casting doubt on the market opportunity. Read More »
Hopes of a hepatitis C-sized market could be dashed by the complexity of and challenges in diagnosing the lesser-known liver disease. Read More »
After several years of dealmaking in the liver disease space, the industry waits for the next wave of assets to mature. Read More »
Follow Lisa LaMotta on Twitter